Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
ConditionRare Tumour
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking University Shenzhen Hospital
About this trial
The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug screening.
Eligibility criteria
Qualifiers
Male or female, the age at the time of signing the informed consent is no less than 18 years old;
Patients with advanced or metastatic rare solid tumor confirmed by histological confirmed;
ECOG score is 0 or 1;
Expected survival ≥12 weeks;
Disqualifiers
No patient lesions available for organoid model construction;
History of interstitial lung disease or radiation pneumonitis of any type;
Central Nervous System (CNS) metastases with brain metastases-related symptoms, which is not stable in neurology, or need to increase steroid dosage to control CNS disease. (Note: Patients with controlled CNS metastasis are eligible to participate in this study);
Current uncontrollable third cavity effusion, such as a large amount of pleural effusion，ascites , or pericardial effusion;
Trial design
Treatments tested in this trial
- Albumin-Bound Paclitaxel
- Epirubicin
- Gemcitabine
- Vinorelbine
- Cisplatin
- Irinotecan
- Fluorouracil
- Nivolumab
- Pembrolizumab
- Durvalumab
- Atezolizumab
- Sintilimab
- Tislelizumab
- Camrelizumab
- Toripalimab
- Serplulimab
- Adebrelimab
- Envafolimab
- Osimertinib
- Alectinib
- Vemurafenib
- Pamiparib
- Pyrotinib
- Imatinib
- Palbociclib
- Savolitinib
- Entrectinib
- Other
Treatment groups
200 Participants
are divided into 4 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov